Emergent Biosolutions, Inc. is on the Cruelty Free Investing use of animals list because they use animals for drug testing and clinical trials.
The company stated in the following press release that they conduct preclinical trials of their drugs on animals.
“Additionally, data from non-clinical and clinical PEP studies that preceded the Phase 3 study have been published in the July issue of Clinical and Vaccine Immunology. The publication describes pre-exposure and post-exposure vaccine efficacy study data in animal models of anthrax disease, as well as exploratory clinical vaccine immunogenicity study data.” Read the full article.
Emergent BioSolutions Inc. is a global specialty biopharmaceutical company focused on the development, manufacture and distribution of a portfolio of medical countermeasures (vaccines, therapeutics and other novel products) and related services for civilian and military populations that address intentional and naturally emerging public health threats, specifically Chemical, Biological, Radiological, Nuclear and Explosive, or CBRNE, threats as well as emerging infectious diseases. The company operations include manufacturing, regulatory affairs, quality assurance, quality control, international sales and marketing and domestic government affairs in support of its portfolio of marketed products, as well as product development and manufacturing infrastructure in support of its portfolio of investigational stage product candidates. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD. [Source: MarketWatch]
Company Website: https://emergentbiosolutions.com